We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BioTime, Inc. announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen® clinical trial
BioTime, Inc. has announced the formation of AgeX Therapeutics, Inc., which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology.